The anti-obesity drugs market is expected to experience substantial growth between 2025 and 2029. As of 2023, the market is valued at USD 2.65 billion, and it is projected to reach USD 6.44 billion by 2029, driven by a compound annual growth rate (CAGR) of 16.20% from 2024 to 2029.
The increasing prevalence of obesity and its associated health risks such as diabetes, cardiovascular diseases, and hypertension are major factors fueling demand for anti-obesity treatments. With rising awareness about